10.28 0.00 (0.00%)
After hours: 5:17PM EDT
|Bid||9.90 x 1400|
|Ask||10.41 x 1800|
|Day's Range||10.25 - 11.20|
|52 Week Range||7.60 - 17.76|
|Beta (3Y Monthly)||2.41|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Co-working giant WeWork is leasing yet another office in Boston, this time a 117,000-square-foot, three-floor spot at 100 Summer St. WeWork will house 2,300 desks at the tower, which Blackstone owns through its EQ Office arm.
While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, increasing oil prices and optimism towards the resolution of the trade war with China, many smart money investors kept their cautious approach regarding the current bull run in the first quarter and hedging or reducing many of their […]
Ironwood (IRWD) and Allergan's Linzess meets the goal in a late-stage study for treating adult patients with IBS-C. Shares rise as the drug reduces bloating, pain and discomfort in IBS-C patients.
Ironwood and Allergan plc (NYSE: AGN) announced positive topline results from a Phase 3b study evaluating Linzess 290 mcg for multiple abdominal symptoms in adult patients with irritable bowel syndrome with constipation, or IBS-C. The companies said the late-stage study met the primary multicomponent endpoint of the drug, when administered orally once-daily, demonstrating an improvement in overall abdominal symptoms of bloating, pain and discomfort in adult patients with IBS-C compared to placebo. Linzess, an FDA-approved drug for IBS-C or chronic idiopathic constipation, or IDC, is marketed in the U.S. by Ironwood and Allergan.
Ironwood Pharmaceuticals Inc NASDAQ/NGS:IRWDView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is moderately high for IRWD with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding IRWD are favorable, with net inflows of $2.49 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
The move comes after longtime Ironwood CEO Peter Hecht left the company to lead spinoff Cyclerion Therapeutics.
Ironwood (IRWD)and its partner initiate dosing in a phase II study evaluating delayed-release version of Linzess, MD-7246, in patients with IBS-D.
Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
On the same day, Marathon issued a letter to e.l.f.’s board that questioned moves by the company to “vary equity grant dates, earnings release dates, forward guidance, and fiscal year end” over the past three years. Marathon said the company acted in a “deliberate manner that consistently benefited [e.l.f.’s] executives” at the expense of shareholders. Marathon also stated that the best remedy for this situation would be to bring aboard additional, fully independent directors, including someone designated to the compensation committee.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Investors can approximate the average market return by buying an index fund. While individual st...
Ironwood (IRWD) misses on both earnings and sales in the first quarter. The company completes its separation into two entities.
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed in recent years. However, hedge funds are generally partially hedged and aim at […]
Ironwood (IRWD) delivered earnings and revenue surprises of -62.50% and -17.33%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Cambridge, Massachusetts-based company said it had a loss of 38 cents per share. Losses, adjusted for non-recurring costs and restructuring costs, came to 26 cents per share. The results missed Wall ...
Ironwood (IRWD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ironwood Pharmaceuticals' (IRWD) Linzess sales are rising and pipeline candidates are progressing well. The company completes separation of its sGC business.
"To be clear, this is not a division between commercial and R-and-D priorities," new Cyclerion CEO Pete Hecht said of the split between the company he founded, Ironwood Pharmaceuticals, and his new firm.